The Supreme Court of India has directed Patanjali Ayurved to submit an affidavit confirming whether its request to remove misleading advertisements from social media platforms has been fulfilled.
The court's directive follows Patanjali Ayurved's submission that sales of 14 products, whose manufacturing was suspended by the Uttarakhand State Licensing Authority, have ceased.
During the proceedings, Patanjali Ayurved informed the court that it had instructed electronic and print media to discontinue advertisements for these medicines. The court, presided over by Justices Hima Kohli and Sandeep Mehta, also appointed Shadan Farasat as amicus curiae in the case.
In related developments, the Indian Medical Association (IMA) informed the court that it had issued apologies across various media platforms and its official website regarding controversial remarks made during the Patanjali hearing.
Senior Advocate PS Patwalia informed the bench that the IMA's website prominently displays an apology notice upon opening, acknowledging the regret expressed and providing an unconditional apology.
Dr. RV Asokan, National President of the IMA, expressed regret to the Supreme Court and submitted an affidavit affirming his apology, emphasising that there was no intention to undermine the court's authority or dignity. The court has scheduled the next hearing for July 30 to further address the matter.
This case stems from the Indian Medical Association's plea to establish guidelines preventing false and misleading advertisements related to Allopathy and Modern Medicine.
Follow us
